Hematology Special Issue

When tyrosine kinase inhibitors benefit patients with CML, can treatment ever be stopped? Experts are looking for an answer.

I don't sign the hospitality guest book. I'm a ghost floating through the corridors. I don't want to make an impact here; don't want to call Roswell Park Cancer Institute home. But when a stranger offers comfort, I'm filled with hope.

Immunotherapy – it's the buzzword of the moment. It would be difficult to imagine an area of the field generating more excitement and hope than immuno-oncology is sparking right now.

September was Blood Cancer Awareness Month, a time to offer support to patients and spread awareness about these diseases both inside and outside the cancer community.

Investigational treatments for myeloproliferative neoplasms promise more than symptom palliation.

By donating stem cells through Be The Match, healthy adults can save the lives of people with blood cancers.

For adults with acute leukemia, CAR T cell immunotherapies, targeted drugs and pediatric chemotherapy regimens are improving outcomes.

Two types of effective treatments for non-Hodgkin lymphoma are cell signaling inhibitors and monoclonal antibodies.

After stem cell transplants for blood cancers, patients -- with help from their caregivers -- must be careful to avoid infections.

With new treatments transforming multiple myeloma into a chronic condition and additional therapies on the horizon, some experts believe a cure is within view.

Researchers say breakthrough blood cancer therapies are worth the high cost. Other experts disagree.